In The News Posted September 7, 2023 Share Posted September 7, 2023 Topline data currently expected late 4Q calendar 2023 Interim analysis of first 120 patients demonstrated: Excellent safety and tolerability product profile Potential for PL9643 to address multiple signs and symptoms of dry eye disease CRANBURY, N.J., Sept. 7, 2023 /PRNewswire/ -- Palatin...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now